KRAS and neoplasm: Across markets, 40%–46% of physicians ranked KRAS/RAS Mut mCRC/first-line as the “number 1” tumor type and treatment setting in which a bevacizumab biosimilar would have the greatest impact on patient outcomes among patients with solid tumors.